(Reuters) – The U.S. Food and Drug Administration on Monday approved Roche Holding AG’s combination therapy for a form of advanced breast cancer that has spread to other parts of the body.
The therapy, Phesgo, was approved for patients with HER2-positive breast cancer and comes with a boxed warning flagging risks of potential heart failure, fetal harm and lung toxicity. (https://bit.ly/3idY5VW)
(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Arun Koyyur)
